Insider · CIK 0001573163
Andrew D. Ashe
officer
Files at VERV (Verve Therapeutics, Inc.). First filing Apr 3, 2025, latest Apr 3, 2025.
Track record
Not enough history
Fewer than three past buys with six months of prices.
Median 6-month excess
-
after past buys, n = 0
Hit rate
-
past buys that beat the index over 6 months
Open-market trades
0 / 1
$0 bought, $11k sold
Signals
This insider’s open-market buys and sells, scored.
| Score | Company | Value | Holdings | Price context | Filed |
|---|---|---|---|---|---|
| 0Weak | Verve Therapeutics, Inc. | $11k 2,681 shares | -1% | - |
Transactions
Every row this insider has filed, newest first.
| Date | Company | Transaction | Shares | Price | Value | Holdings after | Filed |
|---|---|---|---|---|---|---|---|
| Jul 25, 2025 | VERV Verve Therapeutics, Inc. | UTender of shares Common Stock | -348,828 | - | - | 0 | Jul 28, 2025 |
| Jul 25, 2025 | VERV Verve Therapeutics, Inc. | DDisposition to issuer Stock Option (right to buy)derivative | -225,000 | - | - | 0 | Jul 28, 2025 |
| Jul 25, 2025 | VERV Verve Therapeutics, Inc. | DDisposition to issuer Restricted Stock Unitsderivative | -40,000 | - | - | 0 | Jul 28, 2025 |
| Jul 25, 2025 | VERV Verve Therapeutics, Inc. | DDisposition to issuer Restricted Stock Unitsderivative | -27,000 | - | - | 0 | Jul 28, 2025 |
| Jul 25, 2025 | VERV Verve Therapeutics, Inc. | DDisposition to issuer Stock Option (right to buy)derivative | -107,997 | - | - | 0 | Jul 28, 2025 |
| Jul 25, 2025 | VERV Verve Therapeutics, Inc. | DDisposition to issuer Stock Option (right to buy)derivative | -153,278 | - | - | 0 | Jul 28, 2025 |
| Jul 25, 2025 | VERV Verve Therapeutics, Inc. | DDisposition to issuer Stock Option (right to buy)derivative | -26,999 | - | - | 0 | Jul 28, 2025 |
| Jul 25, 2025 | VERV Verve Therapeutics, Inc. | DDisposition to issuer Stock Option (right to buy)derivative | -150,000 | - | - | 0 | Jul 28, 2025 |
| Apr 1, 2025 | VERV Verve Therapeutics, Inc. | MOption exercise Common Stock10b5-1 | +9,000 | - | - | 351,509 | Apr 3, 2025 |
| Apr 2, 2025 | VERV Verve Therapeutics, Inc. | SOpen-market sale Common Stock10b5-1 | -2,681 | $4.15 | $11k | 348,828 | Apr 3, 2025 |
| Apr 1, 2025 | VERV Verve Therapeutics, Inc. | MOption exercise Restricted Stock Unitsderivative10b5-1 | -9,000 | $0.00 | $0 | 27,000 | Apr 3, 2025 |
| Jan 8, 2025 | VERV Verve Therapeutics, Inc. | AGrant or award Stock Option (right to buy)derivative | +225,000 | $0.00 | $0 | 225,000 | Jan 10, 2025 |
| Jan 8, 2025 | VERV Verve Therapeutics, Inc. | AGrant or award Restricted Stock Unitsderivative | +40,000 | $0.00 | $0 | 40,000 | Jan 10, 2025 |
Not investment advice. Scores and forward returns are decision support built from public SEC filings and past prices; they describe what happened after comparable filings, not what will happen after this one. Do your own research and size your risk.